- Home
- PBFS vs PHAT Comparison
PBFS vs PHAT Comparison
Compare PBFS & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBFS
- PHAT
- Stock Information
- Founded
- PBFS 1889
- PHAT 2018
- Country
- PBFS United States
- PHAT United States
- Employees
- PBFS N/A
- PHAT N/A
- Industry
- PBFS Banks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- PBFS Finance
- PHAT Health Care
- Exchange
- PBFS Nasdaq
- PHAT Nasdaq
- Market Cap
- PBFS 287.0M
- PHAT 289.0M
- IPO Year
- PBFS N/A
- PHAT 2019
- Fundamental
- Price
- PBFS $11.58
- PHAT $10.42
- Analyst Decision
- PBFS
- PHAT Strong Buy
- Analyst Count
- PBFS 0
- PHAT 5
- Target Price
- PBFS N/A
- PHAT $16.40
- AVG Volume (30 Days)
- PBFS 28.6K
- PHAT 4.7M
- Earning Date
- PBFS 05-09-2025
- PHAT 08-07-2025
- Dividend Yield
- PBFS N/A
- PHAT N/A
- EPS Growth
- PBFS 27.31
- PHAT N/A
- EPS
- PBFS 0.80
- PHAT N/A
- Revenue
- PBFS $88,641,000.00
- PHAT $81,859,000.00
- Revenue This Year
- PBFS N/A
- PHAT $195.45
- Revenue Next Year
- PBFS N/A
- PHAT $106.76
- P/E Ratio
- PBFS $14.25
- PHAT N/A
- Revenue Growth
- PBFS 21.19
- PHAT 3055.70
- 52 Week Low
- PBFS $9.56
- PHAT $2.21
- 52 Week High
- PBFS $12.20
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- PBFS 54.76
- PHAT 78.59
- Support Level
- PBFS $11.41
- PHAT $4.47
- Resistance Level
- PBFS $11.69
- PHAT $11.28
- Average True Range (ATR)
- PBFS 0.18
- PHAT 1.45
- MACD
- PBFS 0.01
- PHAT 0.38
- Stochastic Oscillator
- PBFS 84.44
- PHAT 76.46
About PBFS Pioneer Bancorp Inc.
Pioneer Bancorp Inc is involved in providing banking services. These services include Personal services such as Checking, Savings, eBanking Cards, and Business services such as Business Deposit and operating Accounts, Business eBanking, and Business loans. Some of the other services of the company include Government Banking, Wealth Management, Benefits Consulting and Insurance.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.